The company may offer and sell up to $200M in the aggregate of common stock, preferred stock, debt securities, warrants, and units.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVS:
- Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
- CRVS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Biotech Alert: Searches spiking for these stocks today
- Corvus Pharmaceuticals granted FDA Fast Track Designation for soquelitinib
- Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024